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Abstract We investigated the association between dietary in-
take of n-3 and n-6 polyunsaturated fatty acids (PUFAs), serum
profiles, and immune and inflammatory markers in juvenile
idiopathic arthritis (JIA) in relation to onset, activity, and dura-
tion. A total of 66 JIA patients and 42 controls were included.
Serum PUFA levels were assessed by gas-liquid chromatogra-
phy-mass spectrometry, a dietary intake by 7-day dietary record
method, and IL-6, IL-10, and IL-17A levels using ELISA.
Dietary PUFA intake did not differ between the JIA group
and controls. Intakes of n-6 and n-3 PUFA and serum levels
were not associated. Levels of total n-6 PUFA and linoleic acid
(LA) were higher in inactive JIA than in active JIA. Patients
with active and short-lasting disease (less than 3 months from
diagnosis) had significantly lower levels of arachidonic acid
(AA) and docosahexaenoic acid (DHA) than the control.
Serum α-linolenic acid (ALA) levels were significantly higher
in poly-JIA than in oligo-JIA and in controls. We found signif-
icantly higher serum IL-10 levels in JIA than in controls. Serum
n-6 and n-3 levels were significantly negatively correlated with
active joint count, erythrocyte sedimentation rate, and C-
reactive protein and positively with platelet count. Our study
presents the low levels of AA and DHA in the active phase of
short-lasting JIA, particularly poly-JIA, and the relationship
between n-6 and n-3 PUFA and classic markers of inflamma-
tion. PUFAs may contribute to the pathogenesis of JIA and
support a necessity to identify new targets suitable for success-
ful interventional studies in JIA patients.
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Introduction
Juvenile idiopathic arthritis (JIA) is the most common chronic
inflammatory articular disease in childhood. Elevation of pro-
inflammatory cytokines has been demonstrated in both serum
and synovial fluid of patients with JIA: tumor necrosis
factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-6 (IL-6),
and interleukin-1β (IL-1β), usually in the active phase of the
disease [1–3]. In remission, the anti-inflammatory interleukin-
10 (IL-10) produced by T-regulatory cells predominates [4].
Fatty acids have numerous functions within the body: they
are structural components of cell membranes, an important
source of energy, and act as signaling molecules. Among them
are long-chain polyunsaturated fatty acids (PUFAs), precur-
sors of endogenous synthesis of pro-inflammatory or anti-
inflammatory lipid mediators. n-6 (omega-6) and n-3
(omega-3) series of PUFA are metabolized by the same set
of enzymes. The membranes of monocytes and macrophages
typically contain large amounts of arachidonic acid (20:4n-6,
AA) compared to a minute load of docosahexaenoic acid
(22:6n-3; DHA) and eicosapentaenoic acid (20:5n-3, EPA).
However, the role of EPA and DHA in inhibition of T cell
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proliferation, decrease in the chemotactic response of leuko-
cytes, reduction of adhesion molecule expression, and de-
crease in the production of inflammatory cytokines requires
further explanation [5].
The arachidonic acid cascade has become a starting point
for a dietary approach based on n-3 PUFA supplementation
and dietary modification of patients with rheumatoid arthritis
(RA). The concern is based primarily on the contention that a
diet rich in linoleic acid (18:2n-6, LA) would promote tissue
AA accumulation, enhance the production of pro-
inflammatory eicosanoids derived from AA, and/or inhibit
the conversion of α-linolenic acid (18:3n-3, ALA) to EPA
and DHA and their subsequent metabolism to predominantly
anti-inflammatory compounds [6, 7]. Some studies indicated
that manipulation in dietary fatty acids can reduce a number of
swollen and tender joints in patients with RA [8, 9], but others
do not confirm these findings [10].
Few records were published regarding the role of PUFA in
JIA. Gheita et al. [11] demonstrated the effect of n-3 PUFA
supplementation on laboratory and clinical parameters of in-
flammation. Górska et al. [12] determined the levels of PUFAs
in relation to cytokines in the active phase of the JIA.
Several studies on the direct relationship between dietary
intake of PUFA and their level in cell membrane phospho-
lipids, adipose tissue, serum, or plasma in a healthy adult
population were published [13–15], but the findings in the
pediatric population are different [16, 17]. Moreover, there is
a shortage of studies comparing the dietary intake of PUFA
and serum PUFA level in patients suffering from different
chronic inflammatory diseases, with JIA in this number.
We performed this study with the aim of finding the asso-
ciation between dietary intake of n-3 and n-6 PUFA, serum
PUFA profile, and immune and inflammatory markers. We
hypothesized that disturbances of the PUFAmetabolism path-
way are dependent on JIA subtype, disease activity, and dis-
ease duration.
Subjects and methods
A total of 66 children with JIA were enrolled in this study,
from three pediatric rheumatology clinics in three centers in
Poland: (i) the Clinic of Paediatrics Rheumatology in
Wroclaw Medical University, (ii) the Department of
Paediatric Pulmonology and Rheumatology Medical
University of Lublin, and (iii) the Department of Children
Rheumatology in John Paul II Paediatrics Centre in
Sosnowiec, between October 2012 and December 2014. The
diagnosis of JIA was based on International League of
Associations for Rheumatology (ILAR) criteria [18].
The patients underwent clinical examination by a pediatric
rheumatologist. The following data was collected: age at dis-
ease onset, age at consent, duration of disease, number of
active/swollen joints, number of joints with limitation of mo-
tion, presence of uveitis, duration of morning stiffness, the
presence of RF, anti-cyclic citrullinated peptide (anti-CCP)
antibodies, anti-nuclear antibody (ANA) positivity, and treat-
ment (drug and dosage).
The patients with JIAwere categorized into six subgroups
according to disease subtype, disease activity, and disease du-
ration from diagnosis. We used the following criteria to define
these groups. The JIA subgroups were defined upon ILAR
criteria [18]. Clinical active JIA was defined as the presence
of at least one joint swelling or limitation of joint motion in
association with pain, warmth, or tenderness of the joint.
Clinical inactive JIA was defined as no joints with active ar-
thritis, no fever, rash, serositis, splenomegaly, or generalized
lymphadenopathy attributable to JIA, no active uveitis, eryth-
rocyte sedimentation rate (ESR) or/and C-reactive protein
(CRP) level within normal limits, and duration of morning
stiffness ≤15min. Short-lasting disease was defined as disease
duration less than 3 months from diagnosis and long-lasting
disease as more than 3 months from diagnosis.
Healthy children were enrolled in the study as a control
group. They had outpatient follow-up in the hospital for rou-
tine medical check-up.
The exclusion criteria for participants of both groups were
chronic autoimmune diseases other than JIA, gastrointestinal
diseases (inflammatory bowel disease, gastritis, and duodenal
ulcers), acute febrile illness, patients on biological therapy,
taking supplements containing n-6 and/or n-3 PUFAs, and
antioxidants.
The study protocol was approved by the Ethics Committee
of Wroclaw Medical University (No. KB 390/2012).
Children’s parents or legal representatives signed a written
informed consent to participate in the study.
Methods
Anthropometric measurements
The body weight and height of all children were measured and
BMI was calculated. Current recommendations for the evalu-
ation of nutritional status of children in a clinical setting re-
garding body weight, height, and BMI percentiles have been
the most useful approach [19]. Our records of the anthropo-
metric measurements were calculated using current Polish
growth charts, followed by height, weight, and BMI parame-
ters in comparison to the relevant percentile curves [20].
The dietary PUFA intake
The analysis of the dietary intake by each study participant
was carried out using a 7-day dietary recording method. In
order to minimize the influence of season on nutrient intake,
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the number of participants in each studied group was matched
with a season of the year. The children’s guardians participat-
ed in the dietary recording. Data on food and beverages con-
sumed and supplements taken during a 7-day period (a week)
were collected and then verified by trained interviewers. The
BPhoto Album of Products and Meals^ was used to estimate
food portion sizes [21]. Data on physical activity (excluding
children less than 7 years old) and taking dietary supplements
were also collected. The daily energy values and an intake of
food components including fat and fatty acids as well as par-
ticipation of energy supply frommacronutrients in individuals
and studied groups were calculated using Dieta 5.0 software
with Polish database (National Food and Nutrition Institute
2015, Warsaw, Poland).
Blood samples and blood tests
On the day of medical examination, the venous blood samples
were collected once from overnight fasted participants from
the JIA group and the healthy control group. Serum was sep-
arated immediately and stored at −70 °C until the analysis of
PUFAs and cytokines.
Complete blood count (CBC), ESR, and CRP, as inflam-
matory markers, were measured as part of routine clinical
assessment in JIA patients.
Polyunsaturated n-6 and n-3 fatty acid serum profiles
Serum n-6 PUFAs LA and AA and n-3 PUFAs ALA, EPA,
and DHAwere detected. The method for extraction and deri-
vation of fatty acids was adapted fromBöcking et al. [22]. The
fatty acid methyl esters were analyzed using a gas
chromatography-mass spectrometry (GLC-MS) system:
Focus GC apparatus with ion trap ITQ 700 (Thermo) and
Trace GC with TSQ Quantum XLS triple quadrupole
(Thermo). For quantitative analysis, tricosanoic acid methyl
ester (C23:0) was added to the examined samples as internal
standard.
Immune markers
The levels of IL-6 and IL-10 (BD Pharmingen, San Diego,
CA) and IL-17A (eBiosciences, San Diego, CA) were deter-
mined in serum samples with enzyme-linked immunosorbent
assays (ELISAs).
Statistical analysis
Chi-squared tests (Pearson’s χ2 test) were used for the back-
ground analysis to test for differences in qualitative variables
between groups. Descriptive statistics were presented as me-
dian and range, respectively. Statistically significant differ-
ences between groups were analyzed using a Mann-Whitney
test. Correlations between variable were examined using
Spearman’s correlation coefficients. All probability values
are two-tailed, and the level of significance was p < 0.05.
Statistical analysis was performed using SPSS for Windows
statistical software (SPSS Inc., Chicago, IL, USA).
Results
The clinical characteristics of the participants in this study are
summarized in Table 1. Both groups were similar according to
age, sex, body height, weight, and BMI. All participants were
Caucasian.
Among the 66 patients with JIA, 38 had an oligo-articular
JIA (oligo-JIA) and 18 had poly-articular JIA (poly-JIA) (RF-
positive and RF-negative). Ten patients having less common
subtypes (systemic JIA (sJIA), psoriatic arthritis, enthesitis-
related arthritis, and undifferentiated arthritis) were combined
into one group because of small numbers and were excluded
from analysis. Fifty-three children have active disease.
Twenty-two children with JIA had a disease duration of
≤3 months, and 44 had >3 months.
Dietary PUFA intake
We did not find significant differences in energy intake from
dietary fats and polyunsaturated fatty acids between JIA pa-
tients and the healthy control (Table 2). There were no signif-
icant differences also in the PUFA intake measured grams pro
day and grams pro MJ between categorized groups (data not
shown). The diet met the recommended total energy and ALA
intake in both groups. LA provided the close-to-
recommended (for children) 4% energy (according to the
European Food Safety Authority (EFSA) 2010, adopted by
the National Food and Nutrition Institute, Warsaw, Poland)
[23], and the n6/n3 ratio, circa 5.5% in both groups, did not
indicate an excessive n6 PUFA level in the diet. However, the
n3 long-chain PUFA intake was very low in the studied chil-
dren and provided less than 0.03% of energy (when measured
grams pro day: 0.031 and 0.066 in JIA and control groups,
respectively, data not shown in Table 2). The median of EPA +
DHA intake comprised only 12 and 26% of recommendation
for children (0.25 g/day) [23].
Serum PUFA profile
Results of serum PUFA level in children with JIA and in the
control group are summarized in Fig. 1.
Our study showed that levels of total n-6 PUFA and LA
were significantly higher in inactive JIA patients compared to
active JIA patients (p = 0.018, p = 0.024, respectively). JIA
patients, particularly active JIA patients and with short-lasting
disease, had significantly lower levels of AA than the healthy
Clin Rheumatol
Table 1 Characteristics of
participants Parameter JIA group, n = 66 Control group,
n = 42
p value
Gender, n (%) 0.44
Male 16 (24.2) 13 (30.9)
Female 50 (75.8) 29 (69.1)
Age, years, median (range) 8.6 (1.5–18) 8.8 (4–17.8) 0.43
Body weight, kg, median (range) 25.05
(10.10–102.00)
28.95 (13.90–70.00) 0.26
Body weight, percentile, n (%)
Less than 25 28 (42.4) 9 (21.4) 0.06
25–75 27 (40.9) 21 (50.0)
Over 75 11 (16.7) 12 (28.6)
Body height, cm, median (range) 127 (77–175) 128 (100–196) 0.38
Body height, percentile, n (%)
Less than 25 20 (30.3) 5 (11.9) 0.07
25–75 35 (53.0) 30 (71.4)
Over 75 11 (16.7) 7 (16.7)
BMI, kg/m2, median (range) 16.45 (12.01–34.40) 17.05 (13.76–30.00) 0.46
BMI, percentile, n (%)
Less than 25 24 (36.4) 10 (23.8) 0.36
25–75 27 (40.9) 19 (45.2)
Over 75 15 (22.7) 13 (31.0)
Subtype of JIA, n (%)
Systemic arthritis 3 (4.5)
Oligoarthritis 38 (57.8)
Oligoarthritis persistent/excendent (n/n) 30/8
Polyarthritis (RF-negative) 12 (18.2)
Polyarthritis (RF-positive) 6 (9.1)
Psoriatic arthritis 1 (1.5)
Enthesitis-related arthritis 5 (7.6)
Undifferentiated arthritis 1 (1.5)
Age at disease onset, years, median (range) 6 (1.1–16)
Disease duration, years, median (range) 1 (0.2–14)
Active/non-active disease 53/13
Joints with active disease, median (range) 2 (0–27)
Duration ofmorning stiffness, min, median (range) 30 (0–120)
Leucocytes/μL, median (range) 7.32 (2.35–62.60)
Leucocytosis, n (%) 12 (18.2)
Anemia, n (%) 5.00 (7.6)
CRP level, mg/L, median (range) 0.88 (0.01–56.31)
Elevated CRP level (>5 mg/L), n (%) 16 (24.2)
ESR, mm/h, median (range) 15 (2–65)
Elevated ESR (>20 mm/h), n (%) 27 (40.9)
RF-positive, n (%) 12 (18.2)
ANA-positive, n (%) 28 (42.4)
Elevated anti-CCP level (>17 U/ml), n (%) 7 (10.6)
Iridocyclitis, n (%) 5 (7.6)
Treatment, n (%)
Non-steroidal anti-inflammatory drugs 36 (54.5)
Methotrexate 48 (72.7)
Chloroquine or hydroxychloroquine 16 (24.2)
Sulfasalazine 9 (13.6)
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control (p = 0.003, p = 0.012, p = 0.002, respectively).
Furthermore, AA levels and total n-3 PUFAwere significantly
lower in JIA patients with short-lasting than with long-lasting
disease (p = 0.009, p = 0.040, respectively). We also found
that ALA level in serum of patients with poly-JIAwas signif-
icantly higher than in the oligo-JIA group and in healthy con-
trols (p = 0.042, p = 0.022, respectively). Levels of DHAwere
significantly lower in active and with short-lasting disease JIA
patients in comparison to the healthy control group (p = 0.015,
p = 0.024, respectively). DHA levels were also lower in active
patients than in inactive patients (p = 0.028).
Cytokines
Table 3 summarizes the serum concentration of IL-6, IL-17,
and IL-10 in children with JIA and the control group. No sig-
nificant differences were found in IL-6 concentration in patients
with JIA compared to the control group, irrespective of the
disease subtype, activity, or duration. We found significantly
higher serum IL-10 levels in JIA patients, especially with active
disease, in oligo- and poly-JIA, as well as in groups of patients
with short-lasting and long-lasting disease in comparison to the
healthy control group (p = 0.008, p = 0.008, p = 0.047,
p = 0.018, p = 0.036, p = 0.020, respectively).
Correlation between dietary intake of PUFAs and serum
PUFA level
We did not find a significant correlation between dietary in-
take and serum level of PUFA between JIA patients and the
healthy control (data not shown).
Association analysis of serum PUFAs and clinical
and laboratory JIA activity markers
We found that the n-3 and n-6 PUFAs negatively correlated
with classical markers of inflammation CRP and ESR
(p < 0.05) and positively correlated with platelet count
(p < 0.05) (Table 4).
Our study revealed that in JIA patients, the total n-6 PUFA,
LA, AA, and DHA levels negatively correlated with the num-
ber of active joints, and the AA, total n-3 PUFA, and EPA
levels positively correlated with duration of the disease
(Table 4). No correlations of PUFA and cytokines were found
(data not shown).
Discussion
To our knowledge, this is the first study that explores the
serum profile of PUFAs in JIA patients without omega-3 fatty
acid supplementation. We aimed to investigate whether the
PUFA metabolic pathway is affected and to what extent in
patients with JIA.
PUFA dietary intake
In our study, dietary intake of PUFA by the JIA patients was
similar to that of the control group. Our findings are consistent
with previous reports which showed no differences in nutrient
intake between sero-negative poly-JIA and oligo-JIA sub-
types, or between the children with active and inactive disease
[24]; no association between fat intake and disease activity
was found either [25]. Such results are not surprising as no
intervention in diet nor n-3/n-6 PUFA supplementation was
designed in this study, and both JIA and healthy children
continued their regular daily diet.
Table 1 (continued)




No treatment 2 (3.0)
ANA anti-nuclear antibodies, anti-CCP anti-citrullinated protein, BMI body mass index, CRP C-reactive protein,
ESR erythrocyte sedimentation rate, NSAID non-steroidal anti-inflammatory drugs, MTX methotrexate, PRE
prednisone, RF rheumatoid factor
Table 2 Dietary fat intake in children with JIA and control group
Nutritional intake JIA group, n = 66 Control group, n = 42 p value
Dietary fat (E%) 26.85 (16.56–47.9) 29.95 (18.4–43.77) 0.88
n-6 PUFA (E%) 3.04 (1.30–4.88) 3.05 (1.30–9.95) 0.25
LA (E%) 2.97 (1.27–4.82) 3.44 (1.77–9.94) 0.60
AA (E%) 0.007 (0.001–0.03) 0.007 (0.001–0.03) 0.09
n-3 PUFA (E%) 0.56 (0.32–1.38) 0.54 (0.27–2.67) 0.50
ALA (%E) 0.48 (0.29–1.13) 0.46 (0.24–1.96) 0.32
EPA (%E) 0.006 (0.00–0.19) 0.007 (0.00–0.60) 0.31
DHA (%E) 0.02 (0.004–0.56) 0.02 (0.002–0.79) 0.69
Values given as median (range)
AA arachidonic acid, ALA α-linolenic acid, DHA docosahexaenoic acid,
EPA eicosapentaenoic acid, FA fatty acids, JIA juvenile idiopathic arthri-

























































































































































































































































































































































































































































































































































































































Fig. 1 Serum PUFA level in children with JIA and in the control group,
in milligrams per liter. a C18:3n3 (ALA). b C20:5n3 (EPA). c C22:6n3
(DHA). d C18:2n6 (LA). eC20:4n6 (AA). f n-3 PUFA. g n-6 PUFA. h n-
3 PUFA/n-6 PUFA. Abbreviations: AA arachidonic acid; ALA α-linolenic
acid, DHA docosahexaenoic acid, EPA eicosapentaenoic acid, FA fatty
acids, JIA juvenile idiopathic arthritis, LA linoleic acid, PUFA
polyunsaturated fatty acids, n3 LA + AA, n6 ALA + EPA + DHA.
*p < 0.05, **p < 0.005



































































All values median (range) are expressed in pg/mL
IL-6 interleukin 6, IL-17 interleukin 17, IL-10 interleukin 10, JIA juvenile idiopathic arthritis
*p < 0.01 vs. BControl group^; p < 0.05 vs. control group
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We found no correlations between dietary and serum
PUFA. A lack of association between dietary intake and blood
fatty acid concentration in children and adults had been re-
ported earlier [16, 26]; to date, other authors found inconsis-
tent correlations in diet supply and serum levels, in n-3 PUFA
(but not n-6) [27, 28], or the opposite [17]. Interestingly, a
recent systematic review demonstrated that LA and AA intake
is reflected by plasma fatty acids, but LA intake had not con-
sistently been shown to increase the conversion of this fatty
acid to AA, nor had AA consistently been shown to affect
EPA or DHA concentration [29].
Among serum PUFA levels, especially DHA seems to be
most sensitive to dietary intake and supplementation [30].
However, it has been shown that adequate dietary ALA intake
may ensure ample DHA level in blood by effective conversion
of ALA in liver [31].We have found significantly lower serum
DHA level in patients with early-stage and active JIA when
compared to the control group despite a lack of differences in
PUFA intake between studied groups of children, as well as
intake of nutrients (dietary fiber, sugars, data not shown)
which have been proven to affect plasma DHA levels in chil-
dren [32]. This may suggest the impeded endogenic synthesis
of DHA in active and short-lasting disease [30, 32]. This result
implies a need for more information from larger, dose-
response studies with meticulous dietary control, especially
in young patients.
Serum PUFA level
The theoretical background of the Blinoleic acid pro-
inflammatory paradigm^ is based on an enhanced synthesis
of pro-inflammatory eicosanoids derived fromAA and dimin-
ished synthesis of anti-inflammatory eicosanoids from EPA
and DHA, observed mostly in in vitro and in multiple animal
experiments [7]. On the other hand, the increasing number of
evidences from human studies suggests that n-6 PUFAs also
provide some anti-inflammatory activity, similarly to n-3
PUFA [29, 33]. We found lower serum levels of AA and
DHA in JIA patients, particularly in active patients and with
short-lasting disease, than in the healthy control group, and
higher n-6 LA level when comparing an inactive vs active
disease period. A decreased concentration of AA and in-
creased concentration of LA in phosphatidylcholine of the
erythrocyte membranes in children with JIA, and during the
active period of JIA, was also reported in another study [12].
Significantly reduced n-3 and n-6 PUFA serum levels were
noted in adult SLE patients [34]. Keeping in mind the results
of our study, we assume that during an active period in the
beginning of a disease the metabolic disturbances occur. They
could be related to desaturation and elongation defects or in-
creased beta-oxidation of lipids [34]. The outcome is an insuf-
ficient concentration of n-3 and n-6 metabolites and predom-










































































































































































































































































































































































































































































































































































































































































































might be the recent data of a crucial role of Bfatty acid
metabolism-immunity nexus^ (FAMIN) protein as the central
regulator of endogenous fatty acid synthesis and their mito-
chondrial oxidation in macrophages. A mutation within the
FAMIN gene was found in children with JIA [35, 36]. A lack
of significant differences in the concentration of LA and ALA
between the JIA group and healthy children (except of higher
ALA level in poly-JIA) may additionally suggest a role of
their metabolites in the mechanism of JIA.
Our observation of the altered blood composition of n-6
and n-3 PUFA is not, as we believe, associated with an inad-
equate provision in the diet: first, in our study, the nutritional
status of children of both groups did not differ on a statistically
significant level; second, our study revealed that dietary PUFA
intake is not associated with serum PUFA. Noteworthily,
Cleary et al. [37] reported that nutritional impairment in JIA
is not an effect from an inadequate food intake, but is associ-
ated with the disease subtype.
Nonetheless, there are too few evidences to define whether
an altered serum PUFA profile could be modified and how
dietary fats may affect disease activity in JIA patients.
Cytokines
We found an increased IL-10 serum level in patients with
active oligo- and poly-JIA, regardless of the disease time span,
in comparison to the healthy control group. Other authors had
published that IL-10 was significantly elevated in specific
subtypes of JIA, e.g., poly-JIA and in sJIA [38, 39]. An in-
crease of IL-10 in the active stage of the disease suggests that
the anti-inflammatory effects may be reduced during systemic
flares [38, 40], or alternatively, that remarkable upregulation
of genes associatedwith IL-10 signaling in recent onset occurs
in untreated JIA patients [41].
No significant differences in the concentration of IL-6 in
patients with JIA compared to the control group, irrespective
of the disease subtype, activity, or duration time, were re-
vealed in our study, which is in agreement with previous data
[2, 24]. To date, IL-6 is mostly attributed to the pathogenesis
of sJIA and elevated serum level is observed in the active
disease period [3, 38]. In our study, however, patients with
sJIA accounted only for 4.5%, as the majority represented
oligo- and poly-JIA types of the disease. van den Ham et al.
[42] showed that oligo- and poly-JIA have similar biomarker
profiles, both in plasma and synovial fluid.
In this study, the serum PUFA level did not correlate with
any of the examined cytokines. Experimental studies revealed
that dietary n-3 PUFA and n-3 PUFA added to cells in vitro did
not affect IL-10 nor IL-6 secretion [43, 44], and interventional
studies in a group of healthy adults stated that habitual intake of
LA and ALA is not related to plasma IL-6 levels [45]. Ferrucci
et al. [46] in a comprehensive study had examined the relation-
ship between PUFA concentration in plasma and inflammatory
marker levels in healthy adults and found that total n-3 fatty
acids were independently associated with decreased level of
pro-inflammatory markers (IL-6, IL-1ra, TNF-α, C-reactive
protein), as well as increased level of anti-inflammatory
markers (soluble IL-6r, IL-10, TGF-β). Altogether, the relation-
ship between PUFA and cytokine production is inconclusive.
Disease activity
The most interesting findings in our study concerned correla-
tions between n-6 and n-3 PUFA levels and clinical activity of
disease as well as registered laboratory parameters.
In the present study, serum n-6, LA, AA, and DHA levels
were inversely associated with number of active joints.
Górska et al. [12] had observed a decreased concentration of
AA in phosphatidylcholine in the erythrocyte membranes dur-
ing the active period of JIA. To our knowledge, the only study
describing an impact of n-3 PUFA supplementation for dis-
ease activity in patients with JIA was published by Gheita
et al. [11] who demonstrated that supplementation of n-3
PUFA (2 g per day over 12 weeks) improved clinical outcome
(by decreasing the amount of active joints, number of swollen
joints, JADAS-27, CHAQ) [11]. Obviously, these findings
need a critical discussion, as the study covered a relatively
small group of patients, and, above all, during the intervention
all the patients were treated with DMARDs: methotrexate,
hydroxychloroquine, leflunomide, sulfasalazine, or steroids,
and there was also no control group or placebo. Thus, it is
unsolved whether the therapeutic effect was in fact a result
of supplementation or traditional medication.
The relationship of PUFAs with the duration of rheumatoid
arthritis was recently shown by Proudman et al. [47], who in
patients with recent RA onset (<12 months) found that a rate
of first remission was significantly higher in the group con-
suming fish oil (providing 5.5 g/day EPA + DHA.). The pos-
itive relationship between serum AA, n-3, EPA level, and
disease duration in our study remains consistent with these
observations and supports the suggestion that the dietary in-
terventions would be justified in the early stages of disease.
We found a strong negative correlation between serum n-6
and n-3 PUFA and the markers of inflammation (ESR, CRP).
The negative relationship between serum n-3 PUFA composi-
tions and correlating CRP level in adults has been reported by
other authors [48, 49]. Pirschon et al. [45] in a large population
found an inverse relationship between an intake of n-3 PUFA
and CRP levels, as well as a strong inverse association between
high n-6 intake and soluble tumor necrosis factor receptors 1
and 2. The authors concluded that the n-3 fatty acids in com-
bination with n-6 fatty acids cause minute decrease of pro-
inflammatory cytokine concentration [45]. Additionally, in
our study we observed that elevated serum total n-6, LA, AA,
total n-3, ALA, and EPA levels were associated with an in-
creased platelet count. Interestingly, platelets activated by pro-
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inflammatory cytokines (e.g., TNF-α, IL-6) play an important
role in the pathogenesis of joint inflammation [50, 51].
Summing up, our data shows that both n-6 and n-3 PUFA
may be engaged in decreasing inflammation during JIA.
Limitations
Although our multicenter study involved altogether a large
group of children with JIA (n = 66), the individual subgroups
are not numerous. The study was designed as a single sight on
assessment; there was no dietary intervention either.
Nevertheless, dividing patients into subgroups allowed us to
present a complete picture of interactions. Using these results,
patients for whom an intervention study could be warranted
have been identified.
Conclusion
To our knowledge, this is the first study that simultaneously
investigated an association between dietary intake of n-3 and n-
6 PUFA, serum PUFA profile, and inflammatory markers
among children with JIA. The combination of reduced levels
of AA and DHA in the active phase of poly-JIA with the in-
creased concentration of IL-10, the inverse relationship of the
two trails (n-6 and n-3), PUFAwith classic markers of inflam-
mation (CRP, ESR), and positive correlation with platelet count
had indicated participation of PUFAs in the early stages of
poly-JIA pathogenesis. Our results may support an identifica-
tion of the target group of patients with JIA to whom PUFA
supplementation in addition to regular daily diet might be rec-
ommended in order to achieve a positive immunomodulating
effect. Further studies and evidences are required, and strongly
advised, prior to incorporation of such therapy in JIA patients.
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